MedTrace Logo

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

NCT01714089 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-04-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

RNS60 125 ml

DRUG

RNS60 250 ml

DRUG

Interferon beta 1a

Sponsors & Collaborators

  • Revalesio Corporation

    lead INDUSTRY

Principal Investigators

  • Fred Lublin, MD, PhD · Mt. Sinai School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01714089 on ClinicalTrials.gov